CTT Pharmaceuticals
2013
FOUNDED
PUBLIC
STATUS
1-10
EMPLOYEES
CTTH
STOCK SYMBOL
$0.21
SHARE PRICE
(As of Friday Closing)
Description
CTT Pharmaceutical Holdings Inc is a development stage company specializing in drug delivery systems technology within the pharmaceutical industry. It focuses on fast-dissolving drug delivery systems through the development of advanced oral delivery thin wafers. The thin wafers are infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternative to smoking and ingestion. Its products include Medwafe, Cannawafe, Vetwafe, and others.
Website
Formerly Known As
Mindesta
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Healthcare Technology Systems
Other Industries
Drug Delivery
Drug Discovery
Stock Exchange
PINX
Primary Office
- 35 Galbraith Drive
- Stoney Creek, Ontario L8G 1Z7
- Canada
+1 (800) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore CTT Pharmaceuticals’s full profile, request a free trial.
CTT Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $0.15 - $0.80 | $0.24 | 39.7K |
CTT Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2016
|
FY 2015
31-Dec-2015
|
FY 2014
31-Dec-2014
|
FY 2013
31-Dec-2013
|
|---|---|---|---|---|
| Enterprise Value | 807 | 309 | 9,001 | 51 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (1,056) | (1,446) | 228 | (19) |
| Net Income | (1,056) | (1,446) | 228 | (19) |
| Total Assets | 45 | 644 | 1,662 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
CTT Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore CTT Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookCTT Pharmaceuticals Executive Team (4)
1 Former Executive
You’re viewing 3 of 4 executives. Get the full list »